Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
STAAR Surgical Company (NASDAQ:STAA) stock is trading lower on Friday after reporting preliminary net sales for the second quarter of over $90 million, compared to net sales of $44.3 million a year ago.
The contact lens company expects a rebound in the Chinese market and solid momentum in the Americas, despite ongoing macroeconomic and geopolitical challenges in certain overseas regions.
Regional Performance And China RecoveryThe quarterly performance was heavily influenced by sequential growth within China, alongside healthy gains throughout the broader Asia-Pacific territory.
Furthermore, the Americas region recorded a double-digit percentage increase in sales, demonstrating solid momentum in that market.
The substantial year-over-year growth is largely tied to normalized operations in China.
During the second quarter of 2025, the company notably limited shipments of its EVO Implantable Collamer Lenses to the country, deliberately allowing local distributors to clear excess stock.
By the end of this recent second quarter, distributor inventory levels had successfully returned to the company’s optimal target range to appropriately serve the refractive market.
Geopolitical Headwinds And EMEA ImpactWhile broader sales remained strong, the Europe, Middle East, and Africa (EMEA) segment experienced a low single-digit percentage decline.
This drop was directly attributed to the ongoing conflict in the Middle East.
However, when excluding Middle Eastern operations, the remainder of the EMEA market achieved double-digit percentage growth, highlighting the resilience of the underlying business across that region.
Significant geopolitical and macroeconomic obstacles continue to weigh on sales in the Middle East, as well as specific areas within the EMEA and Asia-Pacific regions.
Company management remains vigilant in monitoring these conditions, warning that if current headwinds intensify or spread to other global markets, future revenue growth could face negative impacts.
“While geopolitical and macroeconomic pressures continue to present headwinds in certain markets, and while our ERP system implementation presented meaningful operational challenges during the quarter, our team again rose to the occasion and delivered strong results,” said Warren Foust, Co-CEO, President and Chief Operating Officer.
We remain focused on resolving the remaining system issues in the third quarter and are confident in the continued momentum of our business,” Foust commented.
How STAA Ranks On Value And Momentum Versus PeersBelow is the Benzinga Edge scorecard for Staar Surgical, highlighting its strengths and weaknesses compared to the broader market:
Value: Weak (Score: 17.3) — Trading at a steep premium relative to peers. Momentum: Bullish (Score: 90.95) — Stock is outperforming the broader market. The Verdict: Staar Surgical’s Benzinga Edge signal reveals a growth-heavy profile with strong momentum, indicating potential for continued upward movement if the company successfully executes its strategic objectives. However, the low value score suggests caution for investors considering entry points.
STAA Stock Price Activity: Staar Surgical shares were down 8.49% at $26.52 during premarket trading on Friday, according to Benzinga Pro data.
Photo Courtesy: Piotr Swat on Shutterstock.com
Market News and Data brought to you by Benzinga APIs
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced strong preliminary net sales for the second quarter ended July 3, 2026. STAAR is announcing its preliminary net sales in advance of its quarterly earnings announcement, which it expects to issue on August 12, 2026.
Net sales for the second quarter of 2026 are expected to be in excess of $90 million, compared to net sales of $44.3 million for the second quarter of 2025.
The Company delivered strong second quarter net sales, led by sequential growth in China, solid growth across the broader Asia-Pacific region, and double-digit percentage growth in the Americas. In the EMEA region, net sales declined by a low single-digit percentage, reflecting ongoing turmoil in the Middle East; however, excluding the Middle East, EMEA achieved double-digit percentage growth, underscoring the strength of the Company's underlying business across that region.
Net sales in the Middle East, as well as certain parts of the EMEA and Asia-Pacific regions, continued to be adversely affected by significant geopolitical and macroeconomic headwinds, resulting in sales declines in those areas. The Company is actively monitoring these conditions and cautions that, if the current headwinds persist or worsen, then sales growth could continue to be negatively affected. Furthermore, the Company notes that a broadening of macroeconomic challenges to additional regions also could affect future results.
"We are pleased to report that we expect second quarter net sales to be in excess of $90 million, reflecting the strength of our team’s execution and the diversity of our global commercial operations," said Warren Foust, Co-CEO, President and Chief Operating Officer. "While geopolitical and macroeconomic pressures continue to present headwinds in certain markets, and while our ERP system implementation presented meaningful operational challenges during the quarter, our team again rose to the occasion and delivered strong results. We remain focused on resolving the remaining system issues in the third quarter and are confident in the continued momentum of our business."
“Our three core strategic objectives for 2026 continue to be revenue growth, profit expansion, and innovation acceleration. We look forward to providing additional perspective on progress regarding these goals when we report our full second quarter results.”
As previously disclosed, net sales during the second quarter of 2025 were negatively affected as the Company shipped minimal quantities of EVO ICLs to China while distributors worked through excess inventory. As of the end of the second quarter of 2026, distributor inventory appears to be within the Company’s targeted range to appropriately service the refractive market.
The financial information in this release is unaudited and subject to adjustment and confirmation as the Company completes its quarterly review and finalizes its financial statements to be filed with the Company’s Quarterly Report on Form 10-Q for the quarter ended July 3, 2026, and the review of the Company’s independent registered public accounting firm's consolidated financial statements for the quarterly period.
About STAAR Surgical
STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL’s are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye’s natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 4 million ICLs in over 85 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit www.discoverICL.com. To learn more about STAAR, visit http://www.staar.com.
We intend to use our website as a means of disclosing material non-public information about the Company and complying with Regulation FD. Such disclosures will be included on our website in the ‘Investor Relations’ sections at investors.staar.com. Accordingly, investors should monitor such portion of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the Email Alerts section at investors.staar.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often contain words such as “anticipate,” “believe,” “expect,” “plan,” “estimate,” “project,” “continue,” “will,” “should,” “may,” and similar terms. All statements in this press release that are not statements of historical fact are forward-looking statements. These forward-looking statements are neither promises nor guarantees and involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from what is expressed or implied by the forward-looking statements, including, but not limited to: our ability to grow and generate profit; our reliance on independent distributors in international markets; a slowdown or disruption to the Chinese economy; global economic and geopolitical conditions; disruptions in our supply chain; fluctuations in foreign currency exchange rates; international trade disputes (including involving tariffs) and substantial dependence on demand from Asia; changes in effective tax rate or tax laws; any loss of use of our principal manufacturing facility; competition; potential losses due to product liability claims; our exposure to environmental liability; data corruption, cyber-based attacks or network security breaches and/or noncompliance with data protection and privacy regulations; acquisitions of new technologies; climate changes; the willingness of surgeons and patients to adopt a new or improved product and procedure; extensive clinical trials and resources devoted to research and development; compliance with government regulations; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before or after approval, or to take enforcement action; laws pertaining to healthcare fraud and abuse; changes in FDA or international regulations related to product approval; product recalls or failures; and other important factors set forth in the Company’s Annual Report on Form 10-K for the year ended January 2, 2026 under the caption “Risk Factors,” which is filed with the Securities and Exchange Commission (the “SEC”) and available in the “Investor Information” section of the Company’s website under the heading “SEC Filings,” as any such factors may be updated from time to time in the Company’s other filings with the SEC.
Forward-looking statements speak only as of the date they are made and, except as may be required under applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Staar Surgical (STAA - Free Report) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.
The upward trend in estimate revisions for this maker of implantable lenses reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- is principally built on this insight.
The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.
For Staar Surgical, strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year.
The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:
12 Month EPS
Current-Quarter Estimate RevisionsThe company is expected to earn $0.12 per share for the current quarter, which represents a year-over-year change of +123.1%.
Over the last 30 days, the Zacks Consensus Estimate for Staar Surgical has increased 57.14% because one estimate has moved higher compared to no negative revisions.
Current-Year Estimate RevisionsFor the full year, the company is expected to earn $0.59 per share, representing a year-over-year change of +837.5%.
There has been an encouraging trend in estimate revisions for the current year as well. Over the past month, one estimate has moved up for Staar Surgical versus no negative revisions. This has pushed the consensus estimate 28.57% higher.
Favorable Zacks RankThanks to promising estimate revisions, Staar Surgical currently carries a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.
Bottom LineStaar Surgical shares have added 9.5% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales for the first quarter ended April 3, 2026. STAAR is announcing its preliminary net sales in advance of its quarterly earnings announcement because it expects to be interacting with members of the investment community, as well as with surgeons and other members of the ophthalmology community, at the ASCRS Annual Meeting in Washington, D.C.
Net sales for the first quarter of 2026 are expected to be in excess of $90 million, compared to net sales of $42.6 million for the first quarter of 2025.
“We are very pleased with our strong first quarter net sales in our largest market, China, which accounted for the majority of the increase in net sales, along with continued double-digit growth in the Americas. Our higher net sales, combined with our significantly improved cost structure, are expected to drive a meaningful improvement in adjusted EBITDA for the first quarter. These results deliver on two of the three core objectives outlined in our Shareholder Letter earlier this year—Revenue Growth and Profit Expansion—and though early in the year, are indicators of the overall good health of our business,” said Deborah Andrews, Interim Co-CEO and CFO. “Current global business conditions are volatile and some portions of our business remain unpredictable. We continue to provide no forward revenue or earnings guidance and look forward to reporting our full first quarter financial results and filing our 10-Q in early May.”
In the Middle East and some other parts of the EMEA and APAC regions, net sales were negatively affected by significant geopolitical and macroeconomic challenges, resulting in a decline in sales in parts of those regions. The Company is monitoring the situation and cautions that sales growth could continue to be adversely affected if these conditions persist, and that macroeconomic challenges could spread to other regions.
As previously disclosed, net sales during the first quarter of 2025 were impacted as the Company shipped minimal quantities of EVO ICLs to China while distributors worked through excess inventory. As of the end of the first quarter of 2026, distributor inventory appears to be within the Company’s targeted range to appropriately service the refractive market.
The financial information in this release is unaudited and subject to adjustment and confirmation as the Company completes its quarterly review and finalizes its financial statements to be filed with the Company’s Quarterly Report on Form 10-Q for the quarter ended April 3, 2026, and the review of the Company’s independent registered public accounting firm's consolidated financial statements for the quarterly period.
About STAAR Surgical
STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL’s are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye’s natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 4 million ICLs in over 85 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit www.EVOICL.com. To learn more about STAAR, visit http://www.staar.com.
We intend to use our website as a means of disclosing material non-public information about the Company and complying with Regulation FD. Such disclosures will be included on our website in the ‘Investor Relations’ sections at investors.staar.com. Accordingly, investors should monitor such portion of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the Email Alerts section at investors.staar.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often contain words such as “anticipate,” “believe,” “expect,” “plan,” “estimate,” “project,” “continue,” “will,” “should,” “may,” and similar terms. All statements in this press release that are not statements of historical fact are forward-looking statements. These forward-looking statements are neither promises nor guarantees and involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from what is expressed or implied by the forward-looking statements, including, but not limited to: our ability to grow and generate profit; our reliance on independent distributors in international markets; a slowdown or disruption to the Chinese economy; global economic and geopolitical conditions; disruptions in our supply chain; fluctuations in foreign currency exchange rates; international trade disputes (including involving tariffs) and substantial dependence on demand from Asia; changes in effective tax rate or tax laws; any loss of use of our principal manufacturing facility; competition; potential losses due to product liability claims; our exposure to environmental liability; data corruption, cyber-based attacks or network security breaches and/or noncompliance with data protection and privacy regulations; acquisitions of new technologies; climate changes; the willingness of surgeons and patients to adopt a new or improved product and procedure; extensive clinical trials and resources devoted to research and development; compliance with government regulations; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before or after approval, or to take enforcement action; laws pertaining to healthcare fraud and abuse; changes in FDA or international regulations related to product approval; product recalls or failures; and other important factors set forth in the Company’s Annual Report on Form 10-K for the year ended January 2, 2026 under the caption “Risk Factors,” which is filed with the Securities and Exchange Commission (the “SEC”) and available in the “Investor Information” section of the Company’s website under the heading “SEC Filings,” as any such factors may be updated from time to time in the Company’s other filings with the SEC.
Forward-looking statements speak only as of the date they are made and, except as may be required under applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
STAAR Surgical (STAA) expects Q1 net sales to exceed $90M, more than doubling year-over-year, driven primarily by China and double-digit growth in the Americas. Disney plans 1,000 job cuts in marketing overhaul under new CEO.
STAAR Surgical Company has seen a dramatic valuation reset, now trading at a $1bn market cap after failed acquisition talks and underwhelming US growth. Q1 2026 net sales are expected to exceed $90m, driven by a strong rebound in China and signaling potential for record annual revenues. Despite operational challenges and competitive pressures, STAA's proprietary Collamer lens and expanded US indications provide incremental growth opportunities.
Stock futures are pulling back from yesterdays ceasefire-driven outperformance, with futures on the Dow Jones Industrial Average (DJIA), Nasdaq-100 Index (NDX), and S&P 500 Index (SPX) all markedly lower. Despite a decent starting point for negotiations yesterday, U.S.-Iran tensions are renewed after Israel continued with attacks on Lebanon despite the temporary two-week ceasefire. West Texas Intermediate (WTI) crude turned higher, last seen up 4.5%, while the core personal consumption expenditures (PCE) price index rose 3% in February, in line with expectations.
3 levels to watch amid the QQQ breakout. See how our 2026 Top Stock Picks fared in Q1. Plus, beer stock stalls; STAAR breaks out; and Applied Digital earnings disappoint.
5 Things You Need to Know Today The Cboe Options Exchange saw roughly 2.3 million call contracts and 1.3 million put contracts traded Wednesday. The single-session equity put/call ratio fell to 0.56, while the 21-day moving average stayed at 0.60. Constellation Brands Inc (NYSE:STZ) stock is down 1.3% before the open, after the beverage company withdrew its fiscal 2028 outlook, citing weak demand in a constantly changing microenvironment. STZ has been consolidating around $150 since early March, but remains 8% higher year-to-date. STAAR Surgical Co (NASDAQ:STAA) is surging 23.7% premarket, after the lens maker said it expects sales to more than double in Q1. Should these gains hold, STAA will more than erase its year-to-date deficit and continue its recent run higher up the charts. Applied Digital Corp (NASDAQ:APLD) is down 0.7% ahead of the bell, following news the company has not made any new hyperscaler deals, overshadowing a fiscal third-quarter earnings beat. APLD is sporting a 13% gain for 2026. What to expect for the remainder of this week.
European Stocks Take Cue From U.S. Asian markets fell, as the framework around the Iran ceasefire faltered. Japan’s Nikkei and China’s Shanghai Composite both gave back 0.7%, while small caps dragged the South Korean Kospi 1.6% lower. Hong Kong’s Hang Seng shed 0.5%.
In Europe, bourses are mirroring their global counterparts, with travel stocks struggling the most. At last look, London’s FTSE 100 is down 0.3%, while the French CAC 40 and German DAX are 0.6% lower and 1.1% lower, respectively.
STAAR Surgical STAA stock surged more than 25% on Thursday after the ophthalmic implant maker projected first-quarter net sales would top $90 million, more than double the year-ago period.
STAAR Surgical stock jumped as investors reacted to the unexpectedly strong preliminary outlook.
The company attributed the sharp increase largely to a recovery in China, where distributor inventory reductions had weighed on results last year. STAAR Surgical stock also benefited from continued double-digit expansion in the Americas region. STAAR Surgical stock saw improved operating leverage and cost management that are expected to lift adjusted EBITDA meaningfully.
Management noted that the sales rebound in China was accompanied by steady demand across the Americas portfolio. STAAR Surgical stock moved higher even as executives acknowledged lingering pressure from geopolitical tensions and uneven economic conditions in parts of the Middle East, Europe, and Asia-Pacific.
The market expects Staar Surgical (STAA - Free Report) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis maker of implantable lenses is expected to post quarterly earnings of $0.13 per share in its upcoming report, which represents a year-over-year change of +125%.
Revenues are expected to be $91.8 million, up 115.5% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Staar Surgical?For Staar Surgical, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -15.39%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination makes it difficult to conclusively predict that Staar Surgical will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Staar Surgical would post earnings of $0.16 per share when it actually produced earnings of $0.04, delivering a surprise of -75.00%.
Over the last four quarters, the company has beaten consensus EPS estimates three times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Staar Surgical doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
An Industry Player's Expected ResultsAnother stock from the Zacks Medical - Dental Supplies industry, Henry Schein (HSIC - Free Report) , is soon expected to post earnings of $1.2 per share for the quarter ended March 2026. This estimate indicates a year-over-year change of +4.4%. Revenues for the quarter are expected to be $3.33 billion, up 5.1% from the year-ago quarter.
Over the last 30 days, the consensus EPS estimate for Henry Schein has been revised 0.3% down to the current level. Nevertheless, the company now has an Earnings ESP of +0.28%, reflecting a higher Most Accurate Estimate.
This Earnings ESP, combined with its Zacks Rank #3 (Hold), suggests that Henry Schein will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
On May 01, 2026, Staar Surgical Co STAA shares rose 3.1% today, bringing the current price to $27.19. Over the past 52 weeks, the stock has fluctuated between a low of $15.59 and a high of $30.81.
GF Value™ verdict: Current price of $27.19 is 6.6% below GF Value™ of $29.11.GF Score™ of 75/100 indicates that the stock is above average compared to peers.Most notable signal: Insiders have bought $12.3M in shares over the last 3 months with no selling activity. Is STAA Overvalued or Undervalued? Staar Surgical Co's current price of $27.19 is assessed against the GF Value™ of $29.11, signifying that the stock is currently 6.6% undervalued. This margin of safety presents an opportunity for investors who are looking for stocks with potential upside. The GF Valuation label indicates that the stock is fairly valued based on its fundamentals, yet the current trading price suggests that there might still be room for appreciation.
GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Investors should consider this undervaluation alongside other market factors, as undervalued stocks could face risks in terms of volatility and market sentiment.
How Does STAA's Valuation Compare to Its History? Metric Current Historical P/E (TTM) Not available 106.4x Forward P/E 876.8x Not available Currently, Staar Surgical Co's P/E (TTM) is not available, but it is essential to note that the 5-year median P/E stands at 106.4x, while the forward P/E is significantly higher at 876.8x. This suggests that the stock is trading above its historical valuation levels. The P/E analysis aligns with the GF Value™ verdict, reinforcing the notion that the stock may be undervalued based on intrinsic fundamentals but carries risks associated with its high forward P/E.
What Does STAA's GF Score™ Tell Us? Metric Rating GF Score™ 75 Financial Strength 8/10 Profitability 6/10 Growth 7/10 Valuation 10/10 Momentum 1/10 The GF Score™ of 75/100 indicates that Staar Surgical Co is positioned above average relative to its peers, particularly excelling in Financial Strength with a rating of 8/10 and Valuation at 10/10. However, the stock has a weak Momentum ranking of 1/10, suggesting that while the fundamentals are strong, price momentum may not be supportive at this time. The combination of solid financial health and valuation metrics offers a favorable long-term outlook, though the low momentum rank raises caution regarding short-term performance.
What Are Insiders Doing with STAA Stock? Recent insider activity shows a positive trend, with insiders purchasing $12.3 million in shares over the last three months and no recorded selling. This buying pattern suggests confidence from those within the company regarding its future prospects. Such activity often signals that insiders believe the stock is undervalued, which can be an encouraging sign for potential investors.
What This Means for Investors Based on the GF Value™ assessment, Staar Surgical Co STAA is currently undervalued with a fair value estimate of $29.11 compared to the current price of $27.19. The stock's positive financial health and insider buying activity bolster its attractiveness, but investors should remain aware of the high forward P/E and low momentum, which may pose risks.
For the complete analysis, visit the Staar Surgical Co STAA stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is STAA's GF Score™?
STAA has a GF Score™ of 75/100, indicating that it is above average compared to its peers and has the potential to generate higher long-term returns.
Is STAA overvalued or undervalued?
STAA is currently undervalued, with a GF Value™ of $29.11 compared to its current price of $27.19, presenting a potential investment opportunity.
What is STAA's P/E ratio?
The P/E ratio for STAA is not available at this time, but its historical 5-year median P/E is 106.4x, indicating that the stock may be trading above its past valuation levels.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results in combination with a shareholder letter for the first quarter ended April 3, 2026, on Wednesday, May 13, 2026, after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and business progress.
Event: STAAR Surgical First Quarter 2026 Financial Results Webcast
Management will discuss the company’s progress on STAAR’s strategic plan and key market trends, along with first quarter financial results and business updates.
Topics on the call will include:
First Quarter 2026 Financial Results and Operational Performance Execution of Strategic Priorities Revenue Growth Profit Expansion Innovation Acceleration Updates on Dynamics in Key Markets, Including China The live webcast, including an option to pre-register, can be accessed at the preceding link or the “Investors” section of the STAAR website at https://investors.staar.com/. A webcast replay will be available at the same link for at least 90 days.
About STAAR Surgical
STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL’s are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye’s natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 4 million ICLs in over 85 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit www.EVOICL.com. To learn more about STAAR, visit www.staar.com.
Safe Harbor
All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2026 and beyond or prospects for achieving such plans, expectations for sales, revenue, margin, expenses or earnings, and any statements of assumptions underlying any of the foregoing, including those relating to expected or future financial performance. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks and uncertainties related to global economic conditions, as well as the factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 27, 2024 under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investor Information” section of the Company’s website under the heading “SEC Filings.” We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before or after approval, or to take enforcement action; international trade disputes and substantial dependence on demand from Asia; and the willingness of surgeons and patients to adopt a new or improved product and procedure.
We intend to use our website as a means of disclosing material non-public information about the Company and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the ‘Investor Relations’ sections at investors.staar.com. Accordingly, investors should monitor such portion of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the News & Alerts section at https://investors.staar.com/.
Staar Surgical (STAA - Free Report) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to a loss of $0.52 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +192.31%. A quarter ago, it was expected that this maker of implantable lenses would post earnings of $0.16 per share when it actually produced earnings of $0.04, delivering a surprise of -75%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Staar Surgical, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $93.52 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.88%. This compares to year-ago revenues of $42.59 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Staar Surgical shares have added about 22% since the beginning of the year versus the S&P 500's gain of 8.1%.
What's Next for Staar Surgical?While Staar Surgical has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Staar Surgical was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.20 on $79.67 million in revenues for the coming quarter and $0.61 on $312.4 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 22% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, The Cooper Companies (COO - Free Report) , has yet to report results for the quarter ended April 2026. The results are expected to be released on June 4.
This surgical and contact lens products maker is expected to post quarterly earnings of $1.10 per share in its upcoming report, which represents a year-over-year change of +14.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
The Cooper Companies' revenues are expected to be $1.05 billion, up 5.3% from the year-ago quarter.
For the quarter ended March 2026, Staar Surgical (STAA - Free Report) reported revenue of $93.52 million, up 119.6% over the same period last year. EPS came in at $0.38, compared to -$0.52 in the year-ago quarter.
The reported revenue represents a surprise of +1.88% over the Zacks Consensus Estimate of $91.8 million. With the consensus EPS estimate being $0.13, the EPS surprise was +192.31%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Staar Surgical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net Geographic Sales- United States: $6.67 million versus $6.02 million estimated by two analysts on average.Net Geographic Sales- Japan: $12.27 million versus $12.13 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +7.7% change.Net Geographic Sales- China: $47.44 million versus the two-analyst average estimate of $33.75 million. The reported number represents a year-over-year change of +12095.9%.View all Key Company Metrics for Staar Surgical here>>>
Shares of Staar Surgical have returned +15.4% over the past month versus the Zacks S&P 500 composite's +8.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Top 4 Stocks With Notable Insider BuyingSTAAR Surgical NASDAQ: STAA said its first quarter of 2026 marked a sharp rebound in sales and profitability, driven by strong demand in China, continued growth in the U.S. and tighter cost controls following a difficult 2025.
On the company’s earnings call, Interim Co-CEO, President and Chief Operating Officer Warren Foust said STAAR has “now largely moved past many of the challenges” it faced last year, citing disruption related to the potential Alcon merger process, elevated channel inventory in China and tariff risks. Foust said those issues are now “behind us.”
Get STAAR Surgical alerts:
Star Surgical Shines as U.S. Outlook Improves for 2024 STAAR reported first-quarter net sales of $93.5 million, up 119.6% from a year earlier. Deborah Andrews, Interim Co-CEO and Chief Financial Officer, said the increase was driven primarily by strong China sales and double-digit growth in the Americas. Adjusted EBITDA was $24.4 million, compared with an adjusted EBITDA loss of $26.3 million in the prior-year quarter.
Net income was $5.2 million, or $0.10 per diluted share, compared with a net loss of $54.2 million, or $1.10 per diluted share, in the first quarter of 2025. Operating income was $8 million, compared with an operating loss of $57.4 million a year earlier.
China Leads First-Quarter Growth China remained the company’s largest growth driver in the quarter. STAAR reported China net sales of $47.4 million, supported by the commercial launch of EVO+ ICL and continued demand for EVO ICL. Foust said China’s refractive market conditions were more stable in the first quarter than during the more volatile 2022-to-2024 period.
Foust said STAAR entered the quarter with China inventory levels normalized and aligned with contractual targets. He added that the company was able to grow sales while maintaining, and slightly reducing, inventory levels during the quarter. Andrews said the company was pleased that its sales “to the market approximated the sales into the market,” which she described as the desired result of stable distributor inventory.
During the question-and-answer session, Foust said distributor inventory in China is contractually targeted at about six months and is currently “at or below” those levels. He said STAAR had worked through elevated inventory during 2025 and brought it under control by September of that year.
The company also highlighted early demand for EVO+ in China. Foust said surgeon adoption and consumer interest were strong enough that STAAR needed more EVO+ product than initially planned. He said the company expects to fully supply market needs by the end of the second quarter and, for the rest of the year, to supply both EVO and EVO+ for China from its Nidau, Switzerland manufacturing facility.
U.S. Sales Rise Despite Weak Laser Vision Correction Market STAAR also reported its first quarter with more than $6 million in U.S. sales. Foust said U.S. net sales grew 22% year over year despite continued sluggishness in laser vision correction procedures that require removal of corneal tissue.
The company said it received U.S. Food and Drug Administration approval expanding the EVO ICL indication to patients aged 45 to 60. Foust said the expanded label increases STAAR’s addressable market and may open the product to roughly 8 million additional potential patients, though he said it is difficult to quantify the near-term contribution from the expanded indication.
Foust said the U.S. remains under-penetrated relative to more mature ICL markets and continues to represent an important long-term growth opportunity for the company.
Profitability Improves as Spending Falls Gross profit margin was 73.6% of net sales in the first quarter, up from 65.8% in the prior-year period. Andrews attributed the improvement to the elimination of period costs tied to the ramp-up of Swiss manufacturing, lower advanced manufacturing expenses, reduced inventory provisions and lower freight and other cost-of-sales items as a percentage of revenue. These benefits were partially offset by higher per-unit manufacturing costs resulting from lower production volumes in 2025.
Total operating expenses were $60.9 million, down from $85.4 million a year earlier. Excluding restructuring and merger-related costs, operating expenses were $51.5 million, an 18% decrease from $62.7 million in the prior-year quarter. Andrews said the company remains on track with its 2026 spending target of $225 million.
Andrews said STAAR is targeting gross margin of about 75% for the year, though she said the company knew it would fall short of that level in the first quarter. She said the company hopes to exit the year at that level and expects improved unit costs in the second half as volumes increase at the Swiss facility.
STAAR ended the quarter with $163.9 million in cash, cash equivalents and available-for-sale investments, and no outstanding debt. Andrews said cash declined sequentially due to items including seasonal bonuses, employee incentives, global sales meetings, severance and costs associated with a cooperation agreement with Broadwood Partners. She said the company expects to build cash during the rest of the year.
Company Declines to Provide Revenue Guidance STAAR did not provide formal revenue guidance for 2026. Analysts repeatedly asked management about expectations for the second quarter and the seasonal high-demand period in China, but Foust and Andrews declined to endorse consensus estimates or provide a specific forecast.
Foust said the company is optimistic but not ready to make predictions given macroeconomic and geopolitical uncertainty across multiple markets. Andrews said the second quarter is shaping up as she would expect “in a normal Q2 based on historical trends,” but added that STAAR wants more evidence before giving guidance.
“As soon as we feel like we have enough information to accurately predict for you is what we would need to have in order to provide it,” Foust said.
Outside China and the U.S., STAAR said geopolitical and trade-related disruption affected several markets, especially parts of the Middle East. Foust said the net sales impact was limited to less than $2 million. Andrews said ex-China sales grew 6%, with weakness in the Middle East and India limiting growth.
Foust said the broader trend toward lens-based refractive surgery remains a long-term growth driver for STAAR. He also said competition in China, including from Eyebright, has so far been “a non-issue” for STAAR, while adding that the presence of competitors helps validate the lens-based refractive surgery category.
The company also noted that it surpassed 4 million ICLs sold globally during the quarter and continues to roll out a new Oracle ERP system, which management said has caused limited disruption to date.
About STAAR Surgical NASDAQ: STAASTAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in STAAR Surgical Right Now?Before you consider STAAR Surgical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STAAR Surgical wasn't on the list.
While STAAR Surgical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD LiveCustomer Center
My Stock Lists
Email Preferences
Help & Support
Sign Out
Search stocks or keywords
Sections
My IBD
MARKET TREND
STOCK LISTS
STOCK RESEARCH
NEWSECONOMY
VIDEOS & PODCASTS
HOW TO INVESTEDUCATIONAL RESOURCESStoreMy Products
Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD Live
Recently Searched
Travere Stock At 20-Year High, Leads 21 Newcomers To Best Stock Lists Like Big Cap 20
Stock Market Finds Rocket Fuel From Trump Canceling Iran Strikes; SpaceX Debut On Deck
Two AI Titans Flash Entries As Rocket Lab Readies For Launch Staar Surgical (STAA) shares catapulted into a profit-taking zone Thursday after the eye surgery outlet obliterated first-quarter profit expectations. The company, which makes implantable ocular lenses and other tools for ophthalmic surgery, put up adjusted earnings of 41 cents per share. Not only did earnings flip from a year-earlier loss of 52 cents a share, they also walloped forecasts for…
STAAR Surgical Company delivered a robust 1Q26 beat, with revenue up 119% YoY to $93.5M and a swing to $5.2M net income. China's market rebound, normalized inventory, and rapid EVO+ ICL adoption drove topline strength, while disciplined OpEx and manufacturing efficiency boosted margins to 73.6%. STAA is benefiting from a structural shift toward lens-based refractive surgery, gaining U.S. share despite a shrinking laser market and expanding its addressable market via FDA approval.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate in the following upcoming conferences:
Stifel 2026 Virtual Ophthalmology Forum
Date: Tuesday, May 26, 2026
Format: Meetings and Webcast Fireside Chat
Details: Investor meeting participation is by invitation only from the sponsoring brokerage firm.
Webcast: 4:30 PM ET, Webcast Link
Canaccord Genuity Virtual Fireside Chat
Date: Wednesday, May 27, 2026
Format: Webcast Fireside Chat
Details: Registration for the webcast is by invitation only via the sponsoring brokerage firm.
Webcast: 2:30 PM ET
The live and archived webcast for each event, where applicable, will also be available on STAAR’s investor website at https://investors.staar.com.
About STAAR Surgical
STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL’s are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye’s natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 4 million ICLs in over 85 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit www.EVOICL.com. To learn more about STAAR, visit www.staar.com.
Safe Harbor
All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2026 and beyond or prospects for achieving such plans, expectations for sales, revenue, margin, expenses or earnings, and any statements of assumptions underlying any of the foregoing, including those relating to expected or future financial performance. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks and uncertainties related to global economic conditions, as well as the factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 27, 2024 under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investor Information” section of the Company’s website under the heading “SEC Filings.” We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before or after approval, or to take enforcement action; international trade disputes and substantial dependence on demand from Asia; and the willingness of surgeons and patients to adopt a new or improved product and procedure.
We intend to use our website as a means of disclosing material non-public information about the Company and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the ‘Investor Relations’ sections at investors.staar.com. Accordingly, investors should monitor such portion of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the News & Alerts section at https://investors.staar.com/.
On May 28, 2026, Staar Surgical Co STAA shares fell 7.3% to a current price of $29.08. This decline comes amidst a volatile trading period, as the stock has experienced a 52-week range of $15.59 to $35.87.
GF Value™ estimates the fair value at $30.94, indicating the stock is currently 6.0% undervalued.With a GF Score™ of 81/100, Staar Surgical Co is categorized as a strong investment opportunity.Insiders have actively purchased $12.3 million worth of shares in the last three months, signaling confidence in the company's future. Is STAA Overvalued or Undervalued? Staar Surgical Co's current price of $29.08 sits below its GF Value™ of $30.94, reflecting a 6.0% margin of safety for potential investors. This undervaluation suggests that the stock holds an opportunity for appreciation, given that its current market price does not fully reflect its estimated intrinsic value. However, it's crucial to consider that while the GF Valuation label categorizes the stock as fairly valued, the current dip in price might indicate short-term volatility that could affect investor sentiment.
GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Therefore, the current undervaluation may present a buying opportunity, but investors should remain cautious and consider broader market conditions and company fundamentals before making decisions.
How Does STAA's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 82.2x 105.2x Staar Surgical Co's current forward P/E ratio of 82.2x is significantly below its 5-year median P/E of 105.2x, indicating that the stock is trading at a lower valuation compared to its historical averages. This analysis aligns with the GF Value™ verdict of being undervalued, suggesting that the stock may be a compelling prospect for long-term investors seeking growth in the medical devices sector.
What Does STAA's GF Score™ Tell Us? Metric Rating GF Score™ 81/100 Financial Strength 7/10 Profitability 6/10 Growth 6/10 Valuation 9/10 Momentum 10/10 The GF Score™ of 81/100 indicates a strong overall performance, highlighting the company's solid financial strength (7/10) and exceptional momentum (10/10) as its strongest areas. However, the profitability and growth ranks (6/10) suggest there is room for improvement in these aspects. The valuation rank of 9/10 further emphasizes the stock's attractive pricing relative to its intrinsic value, reinforcing the potential upside for investors.
What Are Insiders Doing with STAA Stock? Recent insider activity at Staar Surgical Co has shown significant purchasing, with insiders acquiring $12.3 million in shares over the last three months and no recorded selling. This trend indicates a strong belief among insiders regarding the company's growth prospects and long-term value. Such activity often serves as a positive signal to the market, suggesting that those with the most insight into the company's operations are optimistic about its future performance.
What This Means for Investors Based on the current analysis, Staar Surgical Co is considered undervalued according to the GF Value™ framework. With a strong GF Score™ and favorable insider activity, the stock presents a potential opportunity for investors looking to enter the medical devices market at a reasonable price.
For the complete analysis, visit the Staar Surgical Co STAA stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is STAA's GF Score™?
Staar Surgical Co has a GF Score™ of 81/100, indicating a strong overall performance and potential for higher long-term returns.
Is STAA overvalued or undervalued?
According to GF Value™, Staar Surgical Co is currently undervalued, with a fair value estimate of $30.94 compared to its current price of $29.08.
What is STAA's P/E ratio?
The forward P/E ratio for Staar Surgical Co is 82.2x, which is below its 5-year median P/E of 105.2x, suggesting it is trading at a lower valuation compared to its historical averages.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
What happenedAccording to an SEC filing dated May 14, 2026, Broadwood Capital purchased 1,104,351 shares of STAAR Surgical Company. (STAA 1.83%) during the first quarter, an estimated $21.08 million transaction based on the quarter’s average share price.
The fund’s quarter-end position in STAAR Surgical decreased in value by $45.28 million, a figure that reflects both the additional shares acquired and changes in the stock price over the period.
What else to knowThis was a buy, lifting the stake to 21.25% of Broadwood Capital’s reportable AUM as of March 31, 2026.Top holdings after this filing:NASDAQ:MNST: $587.49 million (41.4% of AUM)NASDAQ:STAA: $301.52 million (21.3% of AUM)NASDAQ:AXON: $294.52 million (20.8% of AUM)NYSEMKT:IWM: $117.78 million (8.3% of AUM)NYSEMKT:LCTX: $78.31 million (5.5% of AUM)As of May 14, 2026, shares were priced at $32.01, up 83.6% over the past year and outperforming the S&P 500 by 56.35 percentage points.Company OverviewMetricValuePrice (as of market close 2026-05-14)$32.01Market capitalization$1.48 billionRevenue (TTM)$290.38 millionNet income (TTM)($21.03 million)Company SnapshotSTAAR Surgical Company develops and sells implantable lenses for vision correction, including the Visian ICL product family for myopia, hyperopia, astigmatism, and presbyopia, as well as preloaded silicone cataract intraocular lenses and injector systems.The company generates revenue primarily through direct sales of its proprietary ophthalmic devices and related delivery systems to healthcare providers and distributors.Main customers are ophthalmic surgeons, vision and surgical centers, hospitals, and government facilities, with a global footprint spanning North America, Europe, and Asia.STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye, leveraging proprietary lens technology to address a broad range of refractive errors.
The company sells its products directly through sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, and through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally.
What this transaction means for investorsNew York-based Broadwood Capital’s purchase of STAAR Surgical Company shares during the first quarter signals the hedge fund has a bullish outlook towards the stock. It already owned over 15 million shares at the end of the fourth quarter of 2025, so adding more in Q1 signals the firm believed the stock would appreciate in value.
The buy made sense at the time. STAAR Surgical shares had dropped to a 52-week low of $15.59 on Feb. 27, which may have been the catalyst for the hedge fund to add to its stake.
Broadwood Capital’s move turned out to be a good one. STARR Surgical’s fiscal Q1 revenue of $93.5 million was the highest first quarter sales in its history. It represented a massive 120% year-over-year increase. The company’s outstanding Q1 was helped by sales growth in the China market.
As a result, STARR Surgical shares soared to a 52-week high of $35.87 on May 14. Due to the increase in its stock price, STARR Surgical’s valuation has skyrocketed. Its forward price-to-earnings ratio is an eye-popping 130. While Broadwood Capital’s Q1 purchase was brilliant, for investors who did not buy, now is not the time to do so.
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Axon Enterprise, Lineage Cell Therapeutics, and Monster Beverage. The Motley Fool has a disclosure policy.
